Details of the presentations are as follows. About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with nash at the american association for the study of To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Nous, Yahoo, faisons partie de la famille de marques Yahoo. Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market Main Business / Finance News Today Gem Digital Limited Commits $50M to Inery in Anticipation of the Coin Launch. You can change your choices at any time by visiting your privacy controls. Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC Approximately 40 patients in the United Kingdom will be enrolled and randomized evenly to receive either 67.8 grams per day of AXA1125 or a matched placebo in two . PDF. Home. Prior to joining Flagship, Mr. Straight Nissen headed up Strategic Portfolio Management for Pfizer's worldwide R&D organization where he oversaw Pfizer's portfolio spanning discovery to Phase 2b across all major therapeutic areas. Mr. Rosiello is an Executive Partner of Flagship Pioneering, where he focuses on building capability to originate, manage, and grow new Flagship companies, and helps drive Flagships strategy, institution building, and growth initiatives. Axcella Therapeutics AXLA, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,. cambridge, mass., october 27, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Axcella Therapeutics (Nasdaq: AXLA ), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM . Slectionnez Grer les paramtres pour grer vos prfrences. axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 20,847,888 shares of If you have an ad-blocker enabled you may be blocked from proceeding. Axcella disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. cambridge, mass., september 12, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. Axcella Therapeutics , a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today . Axcella Therapeutics (Nasdaq: AXLA) today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022. . Word. Send me news from Newsletter. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. . He came to Flagship after a thirty-year career at McKinsey advising CEOs and Boards of leading healthcare, technology and consumer companies. The company entered into a securities purchase agreement with investors to offer 20,847,888 shares of common stock at a purchase price of $1.64 per share. The companys unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. The Shares were offered pursuant to a shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the SEC) and declared effective by the SEC on June 12, 2020. cambridge, mass., october 14, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. 29-09-2022. cambridge, mass. AXLA Valuations. Oct 2009 - Aug 20188 years 11 months. According to analysts' consensus price target of $6.25, Axcella Health has a forecasted upside of 602.2% from its current price of $0.89. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 20,847,888 shares of common stock (the Shares) at a purchase price of $1.64 per share, resulting in gross proceeds of $34.2 million, including $6.0 million received as the cancellation of indebtedness upon the conversion of unsecured subordinated convertible promissory notes held by Flagship Pioneering. The Phase 2a is a randomized, double-blind, placebo-controlled trial that is evaluating the efficacy and safety of AXA1125 in patients with exertional fatigue related to Long COVID. Amount of Analyst Coverage Axcella Health has only been the subject of 3 research reports in the past 90 days. About Axcella Therapeutics (Nasdaq: AXLA) Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic . Title: Development of an allogeneic CAR-T targeting . (RTTNews) - Axcella Therapeutics (AXLA), a clinical-stage biotechnology company developing endogenous metabolic modulators for the treatment of complex diseases . EMMPACT Phase 2b clinical trial . CAMBRIDGE, Mass., November 03, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous . They presently have . Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. The webcast will be accessible in the Investors & News section on the companys website at www.axcellatx.com. Now for opening remarks, I would like to. Company cambridge, mass., february 07, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. At Axcella, we are seeking to unlock the full potential of EMMs by combining a deep understanding of biological pathways with recent advances in systems biology and machine learning. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. . axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the h.c. wainwright 6 th annual nash investor 2021. The institutional investor owned 67,890 shares of the company's stock after purchasing an additional 48,090 shares during the period. Axcella uses the "Investors and News" section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. The company explicitly disclaims any obligation to update any forward-looking statements. arr@lifesciadvisors.com View source version on businesswire.com: https://www.businesswire.com/news/home/20221014005467/en/, LifeSci Advisors Ashley Robinsonarr@lifesciadvisors.com (617) 430-7577, https://www.businesswire.com/news/home/20221014005467/en/, Rouble edges lower after clipping over 2-week high vs dollar, El Salvador Says China Offered to Buy Its External Bond Debt, Russian central bank: No need to ease capital controls further for now, Bayer Profit Boosted by Demand for Seeds and Weed Killer, China warns Taiwan of opposition after Lithuania chip plan. News zur AXCELLA HEALTH AKTIE und aktueller Realtime-Aktienkurs Axcella Health Inc. - 10-Q, Quarterly Report . By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. For more information, please visit www.axcellatx.com. The offering closed on October 13, 2022. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2022-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a . See Top Rated MarketRank Stocks Here About Axcella Health (NASDAQ:AXLA) Stock Find out more about how we use your information in our privacy policy and cookie policy. The information that we post on our website could be deemed to be material information. Thanks from CEO William Hinshaw and the entire Axcella team to Noubar Afeyan of Flagship Pioneering for joining us yesterday to share further. Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting. cambridge, mass., october 13, 2022 -- ( business wire )--axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using. He has provided executive and R&D leadership to biotech and pharmaceutical companies for more than twenty years. cambridge - axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the h.c. wainwright 6th annual nash Axcella intends to use the net proceeds from the offering together with existing cash and cash equivalents to advance the Long COVID program, including regulatory engagement and preparation for further clinical development; advance and complete enrollment of its EMMPACT Phase 2b clinical trial in non-alcoholic steatohepatitis (NASH); and for working capital and other general corporate purposes. X. Nov 7, 2022 Repertoire Immune Medicines, a startup formed in 2020 from the merging of two Flagship Pioneering companies, has scrapped its two lead drugs, replaced its CEO and laid off 65 people . Axcella Health has a 1 year low of $0.85 and a 1 year high of $3.31. CAMBRIDGE, Mass., October 14, 2022--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor Conference taking place virtually on October 17th, 2022. Axcellas pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using . Home; Stock Market News; . The company entered into a securities purchase. Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Nov. 4, 2022, 12:06 AM In a report released on November 1, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health ( AXLA - Research Report ), with a price target of $6.00. Axcella Therapeutics is at . After the quarter ended, it added $28.2 million in cash through a direct offering of common stock. (617) 430-7577, Internet Explorer presents a security risk. About Axcella Therapeutics (Nasdaq: AXLA). . CAMBRIDGE, Mass.-(BUSINESS WIRE)-Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver . Designation provides the potential for an expedited drug development path. Information about your device and internet connection, like your IP address, Browsing and search activity while using Yahoo websites and apps. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. Is this happening to you frequently? Financial Results. En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The companys product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. Shares of Axcella Therapeutics were up almost 20% at $2.07 pre-market, after the US biotech said its experimental treatment for the challenging disease area of non-alcoholic steatohepatitis (NASH) showed statistically-significant improvement in . Earnings Release Financial Exhibit. | November 1, 2022 November 2022. HomeStreet (NASDAQ: HMST) stock hit $25.48 on Tuesday morning, setting a new 52-week low for a change of down 0.23%. Axcellas pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. axcella therapeutics (nasdaq: axla), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (emm) compositions, today announced that the u.s. food and drug administration (fda) has granted a fast track designation to axa1125 for the treatment Nisa Investment Advisors LLC lifted its holdings in StoneCo Ltd. (NASDAQ:STNE - Get Rating) by 242.9% in the second quarter, according to its most recent disclosure with the SEC. Financial Stability. SEC Filings. About Axcella Therapeutics (Nasdaq: AXLA). For more information, please visit www.axcellatx.com. Event for Officers Financial Exhibit New Agreement Other Events October 2022. The end result: Multi-targeted EMM compositions with the potential to address the unmet medical needs of patients with a range of complex conditions.